The United States retains its lead over China in biotechnology, but that lead is narrowing, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative aimed at strengthening America's long-term competitiveness in artificial intelligence. The report, released by (NewsUSA), warns that China could overtake the U.S. in biotechnology by 2030, bolstered by two decades of deliberate national strategy that is now producing results.
The SCSP's Tech Scorecard methodology uses a five-point analysis covering Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage. The United States leads in Innovation Leadership, Market Ecosystem, and Talent Pipeline, while China appears ahead in Industrial Capacity and National Leverage. The report focuses on the biopharmaceuticals sector as an example of China's acceleration in those latter two areas.
According to SCSP analysts, the American position represents "a return on research investments made decades ago, sustained by a capital market that rewards its strongest performers." Most U.S. government funding for biotechnology goes to basic research, and the report notes a lack of urgency in expanding government support for the commercialization of drug products. "Approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy, and can help accelerate, or slow down, the pipeline of innovation," the SCSP authors emphasize.
Both countries invest in basic research, but China is more active in supporting biotech startups through the process of acquiring capital to build pilot capacity, scale up production, and reach markets without waiting for a definitive return on these expanded investments. That strategy includes preferential taxation, below-market lending, and direct subsidies. The U.S. tends to leave this aspect of biotechnology development to the private sector.
The implications extend beyond national prestige. As artificial intelligence allows scientists to predict molecular activity, the expensive early stages of drug discovery are likely to decrease, and the competitive advantage will shift to testing, manufacturing, and commercializing a promising drug candidate. "Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it," the report states.
For readers, the findings signal potential shifts in drug development timelines, manufacturing capacity, and the global supply chain for biopharmaceuticals. For industry, the report highlights the importance of regulatory speed and government support for commercialization, not just basic research. For the world, a narrowing U.S. lead in biotechnology could reshape competition in areas from healthcare to national security. To read the full report and learn more, visit scsp.ai.
